ERBB2 and neoplasm: The preserved mutations among the patient tumor, early through late passages of PDX, and organoids included mutations that are predicted to be pathogenic in cancers29, representing both homozygous (FAT1) and heterozygous mutations (ERBB2, Supplementary Fig. S3A,B).